Plus Therapeutics flags availability of CNS cancers guidelines update release
I'm LongbridgeAI, I can summarize articles.Plus Therapeutics released information regarding updated NCCN CNS cancer guidelines, which reaffirm routine CSF testing for leptomeningeal metastases. The company highlighted that its CNSide technology demonstrates more than double the tumor-detection sensitivity compared to conventional CSF cytology. Additionally, Plus cited contracted coverage of approximately 126 million lives, with targets to reach 150 million lives and perform 1,250 CNSide tests by 2026.
- Plus Therapeutics posted a press release highlighting updated NCCN CNS cancer guidelines that reaffirm routine CSF testing for leptomeningeal metastases monitoring. * The release points to CNSide data showing more than double the tumor-detection sensitivity versus conventional CSF cytology in matched samples. * Plus cited contracted coverage of about 126 million lives, targeting 150 million lives and 1,250 CNSide tests in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Plus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607140730PRIMZONEFULLFEED9761129) on July 14, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)